Current State of COPD with Dr. Gerard Criner


The Temple-based investigator and expert joins Lungcast to review recent clinical trials, recommendations and non-surgical techniques for patients who have advanced COPD.

Episode highlights

0:17 Intro
1:55 Recent GOLD and ATS guideline updates
4:32 PDE-4 inhibitors and antibiotics for COPD
6:34 Best use of lung volume reduction surgery
9:32 Eligibility for lung transplant?
10:23 The ALA Airways Clinical Research Center
12:06 Importance of identifying emphysema
14:00 Treating for COVID-19
17:25 Pandemic effect on ECMO and transplant
18:17 Pulmonary vasculature and supplemental oxygen
21:05 Long COVID-19 symptoms
23:29 Ongoing COPD research at Temple
25:17 Outro

As cases of chronic obstructive pulmonary disease (COPD)—among the leading causes of death in the US—continue to rise nationally and discriminately affect the midwest region, it’s vital to understand the landscape of research and clinical guidance set by leading institutions.

The first Lungcast episode of 2022 provides as good a resource on COPD as is currently available, from the mind of a leading COPD investigator.

Gerard Criner, MD, Chair and Professor of Thoracic Medicine and Surgery at the Lewis Katz School of Medicine at Temple University and Director of the Temple Lung Center, joins Lungcast host Al Rizzo, MD, Chief Medical Officer of the American Lung Association (ALA) for a comprehensive discussion on the state of COPD care and research.

Lungcast is a monthly respiratory health podcast series from the ALA produced by HCPLive.

Through the conversation, Rizzo and Criner touch on leading guidance from the Global Initiative for Chronic Obstructive Lung Disease (GOLD) and American Thoracic Society (ATS) institutions, the evolving priority and strategy of lung transplant, and the effect of COVID-19 on pulmonary care strategies—both acute and chronic.

Subscribe or listen to Lungcast on your favorite platforms:

Related Videos
Reviewing 2023 with FDA Commissioner Robert M. Califf, MD
© 2024 MJH Life Sciences

All rights reserved.